1. Small Molecule Anion Carriers Correct Abnormal Airway Surface Liquid Properties in Cystic Fibrosis Airway Epithelia.
- Author
-
Gianotti A, Capurro V, Delpiano L, Mielczarek M, García-Valverde M, Carreira-Barral I, Ludovico A, Fiore M, Baroni D, Moran O, Quesada R, and Caci E
- Subjects
- Cell Line, Cystic Fibrosis drug therapy, Cystic Fibrosis pathology, Epithelial Cells pathology, Humans, Ion Transport drug effects, Mucus metabolism, Respiratory Mucosa pathology, Cystic Fibrosis metabolism, Cystic Fibrosis Transmembrane Conductance Regulator metabolism, Epithelial Cells metabolism, Ionophores chemical synthesis, Ionophores chemistry, Ionophores pharmacology, Respiratory Mucosa metabolism
- Abstract
Cystic fibrosis (CF) is a genetic disease characterized by the lack of cystic fibrosis transmembrane conductance regulator (CFTR) protein expressed in epithelial cells. The resulting defective chloride and bicarbonate secretion and imbalance of the transepithelial homeostasis lead to abnormal airway surface liquid (ASL) composition and properties. The reduced ASL volume impairs ciliary beating with the consequent accumulation of sticky mucus. This situation prevents the normal mucociliary clearance, favouring the survival and proliferation of bacteria and contributing to the genesis of CF lung disease. Here, we have explored the potential of small molecules capable of facilitating the transmembrane transport of chloride and bicarbonate in order to replace the defective transport activity elicited by CFTR in CF airway epithelia. Primary human bronchial epithelial cells obtained from CF and non-CF patients were differentiated into a mucociliated epithelia in order to assess the effects of our compounds on some key properties of ASL. The treatment of these functional models with non-toxic doses of the synthetic anionophores improved the periciliary fluid composition, reducing the fluid re-absorption, correcting the ASL pH and reducing the viscosity of the mucus, thus representing promising drug candidates for CF therapy., Competing Interests: E.C., O.M. and R.Q. are inventors of a patent application (PCT/EP2019/057696) which protects the composition and use of the compounds described in the present study. The other authors declare no conflict of interest.
- Published
- 2020
- Full Text
- View/download PDF